{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Cancer-Related+Condition&page=14",
    "query": {
      "condition": "Cancer-Related Condition",
      "page": 14
    },
    "page_size": 10
  },
  "pagination": {
    "page": 14,
    "page_size": 10,
    "total_count": 1588,
    "total_pages": 159,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Cancer-Related+Condition&page=15&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Cancer-Related+Condition&page=13&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-23T05:39:08.456Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03198754",
      "title": "Programmed Environmental Illumination (PEI) of Hospital Rooms to Prevent/Reduce Cancer-Related Fatigue",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Cancer-related Problem/Condition",
        "Depression",
        "Circadian Rhythm Disorders"
      ],
      "interventions": [
        {
          "name": "PEI Experimental Light",
          "type": "DEVICE"
        },
        {
          "name": "Comparison Light",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Icahn School of Medicine at Mount Sinai",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "21 Years and older"
      },
      "enrollment_count": 73,
      "start_date": "2016-07-22",
      "completion_date": "2019-01-23",
      "has_results": true,
      "last_update_posted_date": "2020-08-11",
      "last_synced_at": "2026-10-23T05:39:08.456Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03198754"
    },
    {
      "nct_id": "NCT04160052",
      "title": "Venetoclax and Azacitidine for the Treatment of High-Risk Recurrent or Refractory Myelodysplastic Syndrome",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Chronic Myelomonocytic Leukemia",
        "Myelodysplastic Syndrome",
        "Recurrent Myelodysplastic Syndrome",
        "Refractory Myelodysplastic Syndrome",
        "Therapy-Related Myelodysplastic Syndrome"
      ],
      "interventions": [
        {
          "name": "Azacitidine",
          "type": "DRUG"
        },
        {
          "name": "Venetoclax",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 51,
      "start_date": "2019-10-01",
      "completion_date": "2026-02-03",
      "has_results": false,
      "last_update_posted_date": "2026-02-12",
      "last_synced_at": "2026-10-23T05:39:08.456Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04160052"
    },
    {
      "nct_id": "NCT05036408",
      "title": "Cancer Pain Rehabilitation Program to Reduce Pain Related Distress, and Reliance of Pain Medication Through Multimodal Nonpharmacological Solutions",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Hematopoietic and Lymphoid Cell Neoplasm",
        "Malignant Solid Neoplasm"
      ],
      "interventions": [
        {
          "name": "Behavioral, Psychological or Informational Intervention",
          "type": "OTHER"
        },
        {
          "name": "Educational Intervention",
          "type": "OTHER"
        },
        {
          "name": "Manipulative and Body-Based Intervention Procedure",
          "type": "PROCEDURE"
        },
        {
          "name": "Occupational Therapy",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Physical Activity",
          "type": "OTHER"
        },
        {
          "name": "Physical Therapy",
          "type": "PROCEDURE"
        },
        {
          "name": "Questionnaire Administration",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER",
        "PROCEDURE",
        "BEHAVIORAL"
      ],
      "sponsor": "City of Hope Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 16,
      "start_date": "2021-07-21",
      "completion_date": "2024-05-06",
      "has_results": false,
      "last_update_posted_date": "2024-05-29",
      "last_synced_at": "2026-10-23T05:39:08.456Z",
      "location_count": 1,
      "location_summary": "Duarte, California",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05036408"
    },
    {
      "nct_id": "NCT05011058",
      "title": "An Open-Label Phase 2 Trial of Nanatinostat Plus Valganciclovir in Patients With EBV+ Relapsed/Refractory Lymphomas",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Epstein-Barr Virus Associated Lymphoma",
        "EBV-Positive DLBCL, NOS",
        "EBV-Related Non-Hodgkin Lymphoma",
        "EBV Related PTCL, NOS",
        "EBV-Related Hodgkin Lymphoma",
        "EBV-Related PTLD",
        "EBV-Related Lymphoproliferative Disorder"
      ],
      "interventions": [
        {
          "name": "Nanatinostat in combination with valganciclovir",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Viracta Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 102,
      "start_date": "2021-05-28",
      "completion_date": "2025-01-31",
      "has_results": true,
      "last_update_posted_date": "2025-07-28",
      "last_synced_at": "2026-10-23T05:39:08.456Z",
      "location_count": 17,
      "location_summary": "Birmingham, Alabama • Duarte, California • Los Angeles, California + 14 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05011058"
    },
    {
      "nct_id": "NCT00000626",
      "title": "Phase II Study of Filgrastim (G-CSF) Plus ABVD in the Treatment of HIV-Associated Hodgkin's Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "HIV Infections",
        "Hodgkin's Disease"
      ],
      "interventions": [
        {
          "name": "Vinblastine sulfate",
          "type": "DRUG"
        },
        {
          "name": "Dacarbazine",
          "type": "DRUG"
        },
        {
          "name": "Filgrastim",
          "type": "DRUG"
        },
        {
          "name": "Bleomycin sulfate",
          "type": "DRUG"
        },
        {
          "name": "Doxorubicin hydrochloride",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 27,
      "start_date": null,
      "completion_date": "1999-02",
      "has_results": false,
      "last_update_posted_date": "2021-10-27",
      "last_synced_at": "2026-10-23T05:39:08.456Z",
      "location_count": 8,
      "location_summary": "Birmingham, Alabama • Los Angeles, California • Chicago, Illinois + 4 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00000626"
    },
    {
      "nct_id": "NCT04713202",
      "title": "Prospective Assessment of Patients With Neuroendocrine Tumors and Current or Prior History of Carcinoid Syndrome or Diarrhea Undergoing Peptide Receptor Radionuclide Therapy With or Without Telotristat Ethyl",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Neuroendocrine Tumors",
        "Carcinoid Syndrome",
        "Diarrhea"
      ],
      "interventions": [
        {
          "name": "Telotristat ethyl",
          "type": "DRUG"
        },
        {
          "name": "Peptide Receptor Radionuclide Therapy",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Chandrikha Chandrasekhara",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2021-03-03",
      "completion_date": "2024-02",
      "has_results": false,
      "last_update_posted_date": "2023-02-10",
      "last_synced_at": "2026-10-23T05:39:08.456Z",
      "location_count": 1,
      "location_summary": "Iowa City, Iowa",
      "locations": [
        {
          "city": "Iowa City",
          "state": "Iowa"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04713202"
    },
    {
      "nct_id": "NCT00425802",
      "title": "Chemotherapy, Total-Body Irradiation, Rituximab, and Donor Stem Cell Transplant in Treating Patients With B-Cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Leukemia",
        "Lymphoma"
      ],
      "interventions": [
        {
          "name": "anti-thymocyte globulin",
          "type": "BIOLOGICAL"
        },
        {
          "name": "filgrastim",
          "type": "BIOLOGICAL"
        },
        {
          "name": "graft-versus-tumor induction therapy",
          "type": "BIOLOGICAL"
        },
        {
          "name": "rituximab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "cyclosporine",
          "type": "DRUG"
        },
        {
          "name": "fludarabine phosphate",
          "type": "DRUG"
        },
        {
          "name": "mycophenolate mofetil",
          "type": "DRUG"
        },
        {
          "name": "nonmyeloablative allogeneic hematopoietic stem cell transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "total-body irradiation",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "PROCEDURE",
        "RADIATION"
      ],
      "sponsor": "Memorial Sloan Kettering Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 61,
      "start_date": "2006-11-28",
      "completion_date": "2016-10-28",
      "has_results": true,
      "last_update_posted_date": "2017-10-31",
      "last_synced_at": "2026-10-23T05:39:08.456Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00425802"
    },
    {
      "nct_id": "NCT00093353",
      "title": "N2003-01: Irinotecan, Temozolomide, and Cefixime in Treating Young Patients With Recurrent or Resistant Neuroblastoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Diarrhea",
        "Drug/Agent Toxicity by Tissue/Organ",
        "Neuroblastoma"
      ],
      "interventions": [
        {
          "name": "cefixime",
          "type": "DRUG"
        },
        {
          "name": "irinotecan hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "temozolomide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "New Approaches to Neuroblastoma Therapy Consortium",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Year",
        "maximum_age": "30 Years",
        "sex": "ALL",
        "summary": "1 Year to 30 Years"
      },
      "enrollment_count": 30,
      "start_date": "2004-05",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2026-04-14",
      "last_synced_at": "2026-10-23T05:39:08.456Z",
      "location_count": 13,
      "location_summary": "Los Angeles, California • Palo Alto, California • San Francisco, California + 9 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00093353"
    },
    {
      "nct_id": "NCT03266653",
      "title": "EBV-specific Cytotoxic T-lymphocytes (CTLs) for Refractory EBV Infection",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Epstein-Barr Virus Infections",
        "Primary Immune Deficiency Disorder"
      ],
      "interventions": [
        {
          "name": "cytotoxic t-lymphocytes",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "New York Medical College",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Month",
        "maximum_age": "79 Years",
        "sex": "ALL",
        "summary": "1 Month to 79 Years"
      },
      "enrollment_count": 20,
      "start_date": "2020-07-07",
      "completion_date": "2027-12-31",
      "has_results": false,
      "last_update_posted_date": "2025-08-08",
      "last_synced_at": "2026-10-23T05:39:08.456Z",
      "location_count": 8,
      "location_summary": "Los Angeles, California • San Francisco, California • Baltimore, Maryland + 5 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Valhalla",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03266653"
    },
    {
      "nct_id": "NCT00003583",
      "title": "Amifostine to Prevent Side Effects in Patients Who Are Receiving Chemotherapy and Radiation Therapy for Limited-Stage Small Cell Lung Cancer",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Drug/Agent Toxicity by Tissue/Organ",
        "Lung Cancer",
        "Radiation Toxicity"
      ],
      "interventions": [
        {
          "name": "amifostine trihydrate",
          "type": "DRUG"
        },
        {
          "name": "cisplatin",
          "type": "DRUG"
        },
        {
          "name": "etoposide",
          "type": "DRUG"
        },
        {
          "name": "radiation therapy",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION"
      ],
      "sponsor": "University of Florida",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "1997-06",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2013-12-04",
      "last_synced_at": "2026-10-23T05:39:08.456Z",
      "location_count": 1,
      "location_summary": "Gainesville, Florida",
      "locations": [
        {
          "city": "Gainesville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00003583"
    }
  ]
}